Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
Table 2
Characteristics associated with death following diagnosis of NSCLC, stage IIIB/IV for patients receiving C/C+G or C/C+T first-line chemotherapy.
Characteristics
95% CI
Hazard ratio
Lower limit
Upper limit
Age at diagnosis
1.009
1.001
1.018
.0339
Sex
Male
1.310
1.207
1.422
.0001
Female
1.00 (Referent)
Stage at diagnosis
IV
1.376
1.266
1.495
.0001
IIIB
1.00 (Referent)
Race
Non-Hispanic Caucasian
1.069
0.932
1.226
0.3374
Other
1.00 (Referent)
Comorbidity
Charlson 1
1.204
0.991
1.464
0.0617
Charlson 1
1.00 (Referent)
SEER registry region
Northeast
0.999
0.897
1.113
0.9878
Midwest
1.044
0.935
1.166
0.4467
South
1.036
0.930
1.153
0.5253
West
1.00 (Referent)
Location of residence
Metro
1.001
0.893
1.121
0.9916
Other
1.00 (Referent)
Histology
Nonsquamous cell
1.138
1.034
1.251
0.0079
Squamous cell
1.00 (Referent)
Primary treatment
C/C+G
1.137
0.900
1.436
0.2825
C/C+T
1.00 (Referent)
Histology*treatment interaction
Nonsquamous*C/C+G
0.857
0.656
1.119
0.2561
Notes: C/C+G: cisplatin/carboplatin and gemcitabine, C/C+T: cisplatin/carboplatin and taxane.
